本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/4/241 分钟阅读
Egis Pharmaceuticals Limited, et al.; Withdrawal of Approval of Three Abbreviated New Drug Applications
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of three abbreviated new drug applications (ANDAs) from the holders of those ANDAs. The basis for the withdrawal is that the ANDA holders have repeatedly failed to file required annual reports for those ANDAs.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →